Chugai’s Bispecific Antibody “ERY974″ Results of Preclinical Study Published in Science Translational Medicine

05-Oct-2017 Intellasia | BusinessWire | 8:20 AM Print This Post

– Chugai’s Research Findings Adopted by World-Class Academic Journal -

TOKYO–(BUSINESS WIRE)–#antibodyChugai
Pharmaceutical Co., Ltd.
(TOKYO: 4519) announced today that the
preclinical study findings on its original bispecific antibody ERY974, a
molecule that binds Glypican-3 and CD3 simultaneously, and that is
currently under development as a Phase I clinical study for solid
tumors, were published in the online edition of Science Translational
on October 4, 2017 (local time) (
Translational Medicine
is a member of the Science Magazine
family of journals and is an essential platform for peer-reviewed,
multidisciplinary research driving the latest medical advances.

“ERY974 is a bispecific antibody created under the joint research
between Chugai and Chugai Pharmabody Research with the application of
Chugai’s proprietary innovative antibody engineering technologies. We
are extremely pleased that our research findings on ERY974 have been
published in Science Translational Medicine,” said Dr. Hisafumi
Okabe, Senior Vice President responsible for Research and Translational
Clinical Research. “It is said that cancer immunotherapy has made a
paradigm shift in cancer treatment and that the role of the immune
system in cancer treatment is likely to continue to grow in the future.
As a cancer immunotherapy, we have high hopes that ERY974 will
demonstrate anti-tumor effects in future clinical studies and become a
drug that can contribute to the treatment of patients.”

Glypican-3 (GPC3) is a membrane protein that is expressed with high
frequency on the cellular membranes of various tumor cells including
hepatocellular carcinoma, lung cancer, and gastric cancer. GPC3 is
reported to be expressed in various tissues in the fetal stage and play
an important role*, but is rarely expressed in normal adult tissues*. As
GPC3 expression is observed through the malignant transformation of
cells, GPC3 is thought to be a protein specific to cancer
(tumor-associated antigen)*.

ERY974 is a bispecific antibody that binds to both GPC3 on the cancer
cell membrane and to CD3, a membrane protein expressed on T cells, a
type of lymphocyte. ERY974 is a T cell Redirecting
(TRAB) created with Chugai’s proprietary antibody engineering
technology, and while simultaneously binding to GPC3 and CD3 and
directing T cells to cancer cells, it also activates T cells,
specifically attacking and killing neighboring cancer cells. Based on
this mechanism whereby it activates T cells and attacks cancer cells,
TRAB is classified as a type of cancer immunotherapy.

The following points were shown in this research:

  • According to the immunohistochemistry, GPC3 is expressed in various
    cancers (a hepatocellular carcinoma, a squamous lung cancer, a small
    cell lung cancer, an esophageal cancer, a gastric cancer and a head
    and neck cancer), and as previously reported *, it is rarely expressed
    in normal tissues (30 different tissues) (in vitro)
  • GPC3-dependent T cell activation and killing of cancer cells by ERY974
    was observed in vitro
  • In three different experimental tumor models using mouse, ERY974
    demonstrated anti-tumor effects
  • Anti-tumor effects were observed even in cancers where other cancer
    immunotherapies are ineffective (Mouse)
  • Tolerability of ERY974 was observed in toxicity testing in animal

Based on the results of this preclinical study, Chugai began phase I
clinical trial of ERY974 in patients with GPC3 positive solid tumors in
the United States in August 2016 (NCT02748837).

As a leading company in the field of antibody therapeutics, Chugai will
continue to contribute to global healthcare and the health of all people
through the creation of innovative treatments using its proprietary
antibody technologies.

* D. Baumhoer, L, Tornillo, S. Stadlmann, M. Roncalli, E. K. Diamantis,
L. M. Terracciano, Glypican 3 expression in human nonneoplastic,
preneoplastic, and neoplastic tissues: a tissue microarray analysis of
4,387 tissue samples. Am J Clin Pathol. 129, 899-906

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
In Japan, Chugai’s research
facilities in Gotemba and Kamakura are collaborating to develop new
pharmaceuticals and laboratories in Ukima are conducting research for
technology development for industrial production. Overseas, Chugai
Pharmabody Research
based in Singapore is engaged in research
focusing on the generation of novel antibody drugs by utilizing Chugai’s
proprietary innovative antibody engineering technologies. Chugai
Pharma USA
and Chugai
Pharma Europe
are engaged in clinical development activities in the
United States and Europe.
The consolidated revenue in 2016 of
Chugai totalled 491.8 billion yen and the operating income was 80.6
billion yen (IFRS Core basis).
Additional information is available
on the internet at


For Media
Chugai Pharmaceutical Co.,
Media Relations Group, Corporate Communications Dept.,
Tel: +81-3-3273-0881
E-mail: [email protected]
US media

Chugai Pharma USA Inc.
Casey Astringer
E-mail: [email protected]
European media

Chugai Pharma France SAS
Nathalie Leroy
E-mail: [email protected]
Taiwanese media

Chugai Pharma Taiwan Ltd.
Susan Chou
E-mail: [email protected]

Chugai Pharmaceutical Co., Ltd.
Relations Group, Corporate Communications Dept.,
Toshiya Sasai
E-mail: [email protected]


Category: BusinessWire, PRAsia

Print This Post